Compelo Medical Devices is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More

Dako and Omnyx introduce digital pathology solution for breast cancer diagnostics

Dako, a Danish provider of tissue-based cancer diagnostics, and Omnyx, a joint venture of GE Healthcare and the University of Pittsburgh Medical Center, have launched clinical image analysis for digital pathology in Europe.

As part of the partnership formed in 2010 for developing clinical algorithms for digital pathology, Dako has used capability in staining and image analysis to develop image analysis algorithms that are incorporated into the Omnyx digital pathology platform.

With this offering, both the companies will help support pathologists in making confident, efficient diagnoses based on both subjective and quantitative measures.

Additionally, the algorithms link digital scanners to Dako reagents and staining instruments, which give customers a complete and integrated solution.

Omnyx CEO Jim LaFrance noted the company envisions a future where image analysis and workflow empower pathologists to make confident clinical decisions ultimately leading to better patient care.

"Our partnership with Dako allows us to offer image analysis to clinicians who use Dako tests. Image analysis for prognostic markers within the Omnyx Integrated Digital Pathology workflow provides pathologists with a powerful set of tools to improve both accuracy and efficiency," LaFrance added.

The HercepTest image analysis tool is now accessible in the Omnyx system and has been specifically customized for Dako’s breast cancer prognostic markers.